5 Most Undervalued Biotech Stocks to Buy According to Analysts

In this article, we will take a look at the 5 most undervalued biotech stocks to buy according to analysts. To read our analysis of the recent trends and market activity, you can go to the 11 Most Undervalued Biotech Stocks to Buy According to Analysts.

5. Moderna, Inc. (NASDAQ:MRNA)

Upside Potential as of August 14: 83.25%

PE Ratio (TTM) as of August 14: 8.52

Number of Hedge Fund Holders: 40

Cambridge, Massachusetts-based Moderna, Inc. (NASDAQ:MRNA) is a leading biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. In addition to the commercial stage covid19 vaccine, the clinical pipeline of the company includes therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases.

On August 3, Moderna, Inc. (NASDAQ:MRNA) released its financial results for Q2 2023 and provided business updates. The company expects COVID-19 vaccine sales of $6 billion to $8 billion in 2023, dependent on U.S. vaccination rates. Four infectious disease vaccines being developed by the company are in Phase 3 trials stage including RSV, and neoantigen therapy melanoma, among others.

Moderna, Inc. (NASDAQ:MRNA) ranks #1 on our list of 11 most undervalued biotech stocks to buy according to analysts based on the number of hedge funds that held its shares at the end of Q2 2023. Its shares were owned by 40 leading hedge funds with the total shares held by them valued at nearly $2.0 billion.